skip to the content

Welcome to MabThera.com

MabThera.com is a comprehensive resource for healthcare professionals outside the United States who are interested in MabThera (rituximab) and the treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukaemia (CLL). This site also provides information on NHL and CLL epidemiology, diagnosis, staging and prognostic factors. Data from pivotal clinical trials of MabThera in NHL and CLL, including new data on the use of MabThera maintenance in first-line follicular lymphoma (FL), are available.

About CLL

Here you can learn more about CLL, including current practice in diagnosis and classification.

Learn more

Treating CLL

Click here to learn about the treatment of CLL.

Learn more

About NHL

Here you can learn more about NHL, including current theories relating to disease aetiology and current practice in diagnosis and classification.

Learn more

Treating NHL

Click here to learn more about the treatment of NHL, including FL and diffuse large B-cell lymphoma (DLBCL).

Learn more

MabThera product characteristics

MabThera product characteristics

Get access to the MabThera Summary of Product Characteristics